Literature DB >> 9392012

Oculopharyngeal muscular dystrophy in France.

M Fardeau1, F M Tomé.   

Abstract

The clinical, histopathological, ultrastructural and geographical data on 29 cases of oculopharyngeal muscular dystrophy (OPMD) identified by the authors in France is briefly presented. The mean age of the patients was 53.8 +/- 8.1 years. Onset symptoms were ptosis (14/29), dysphagia (12/29) and limb girdle weakness (3/29). The evolution of the disease was always progressive and followed different clinical patterns. The main histological changes in muscle biopsies were atrophic angulated fibers (29/29) and rimmed vacuoles (25/29); muscle fiber necrosis was very rare (1/29). The characteristic nuclear inclusions made of 8.5-nm filaments were observed in all cases, and found in 2-5% of the nuclei in a given ultrathin section. They are the morphological marker of the disease.

Entities:  

Mesh:

Year:  1997        PMID: 9392012     DOI: 10.1016/s0960-8966(97)00078-3

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

1.  Muscular involvement assessed by MRI correlates to motor function measurement values in oculopharyngeal muscular dystrophy.

Authors:  Arne Fischmann; Monika Gloor; Susanne Fasler; Tanja Haas; Rachele Rodoni Wetzel; Oliver Bieri; Stephan Wetzel; Karl Heinimann; Klaus Scheffler; Dirk Fischer
Journal:  J Neurol       Date:  2011-02-22       Impact factor: 4.849

2.  Genotype and phenotype study of 34 Spanish patients diagnosed with oculopharyngeal muscular dystrophy.

Authors:  Mireia Tondo; Josep Gámez; Eduardo Gutiérrez-Rivas; Ramón Medel-Jiménez; Loreto Martorell
Journal:  J Neurol       Date:  2012-01-10       Impact factor: 4.849

3.  Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy: a retrospective study with implications for trial design.

Authors:  Sarah Youssof; Ronald Schrader; David Bear; Leslie Morrison
Journal:  Neuromuscul Disord       Date:  2014-11-20       Impact factor: 4.296

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.